Beta Bionics, Inc.
No enriched coverage for $BBNX in the last 7 days.
Beta Bionics (BBNX) CCO Mark Hopman sold 775 shares for $13,446 at $17.35-$18.35/share. BBNX stock is down 7.3% this week but up 26% in six months. The company received FDA clearance for its Mint patch pump, revised fiscal 2026 revenue guidance downward, and announced a $125M stock offering. Analysts from UBS, Jefferies, and Wells Fargo maintain positive ratings and price targets.
Beta Bionics, Inc. faces a proposed investor lawsuit over alleged misleading statements about its iLet insulin-delivery system. The FDA found gaps in complaint handling, including 107 severe hypoglycemia reports and 500 cartridge leak complaints. The company denies wrongdoing and plans to defend itself. The lawsuit covers investors who bought shares from July 2025 to February 2026.
Jefferies initiated coverage on Beta Bionics (NASDAQ:BBNX) with a Buy rating and $30 price target, citing insulin pump tech and upcoming launches. Stock trades at $17.63, up 99% in six months. Company plans $125M stock offering and revised 2026 revenue guidance down. Analysts have mixed views on Mint pump's growth potential.
Recent BBNX coverage spans financial news, regulation and corporate actions.
In the last 30 days, BBNX insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($20K). The most active reporter was Hopman Mark, Chief Commercial Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may signal limited confidence and could weigh on the stock.
Beta Bionics, Inc. faces a proposed investor lawsuit over alleged misleading statements about its iLet insulin-delivery system. The FDA found gaps in complaint handling, including 107 severe hypoglycemia reports and 500 cartridge leak complaints. The company denies wrongdoing and plans to defend itself. The lawsuit covers investors who bought shares from July 2025 to February 2026.
New sell-side initiation plus a detailed catalyst stack (Mint launch, DME/pharmacy transition, share gains) can re-rate near-term expectations, but the article also flags revised 2026 revenue guidance downward.
Positive rating and growth expectations should support Beta Bionics stock.
Barclays initiated coverage of Beta Bionics with an Overweight rating and a $30 price target. The stock is currently trading at $18.63, down 4.02% year-to-date. Previously, Truist raised its price target to $28 with a Buy rating.
AlphAI scores every news story that mentions BBNX with an AI model for sentiment and relevance, and aggregates insider trades from Beta Bionics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Beta Bionics (BBNX) CCO Mark Hopman sold 775 shares for $13,446 at $17.35-$18.35/share. BBNX stock is down 7.3% this week but up 26% in six months. The company received FDA clearance for its Mint patch pump, revised fiscal 2026 revenue guidance downward, and announced a $125M stock offering. Analysts from UBS, Jefferies, and Wells Fargo maintain positive ratings and price targets.
2 min readBeta Bionics, Inc. faces a proposed investor lawsuit over alleged misleading statements about its iLet insulin-delivery system. The FDA found gaps in complaint handling, including 107 severe hypoglycemia reports and 500 cartridge leak complaints. The company denies wrongdoing and plans to defend itself. The lawsuit covers investors who bought shares from July 2025 to February 2026.
1 min readJefferies initiated coverage on Beta Bionics (NASDAQ:BBNX) with a Buy rating and $30 price target, citing insulin pump tech and upcoming launches. Stock trades at $17.63, up 99% in six months. Company plans $125M stock offering and revised 2026 revenue guidance down. Analysts have mixed views on Mint pump's growth potential.
4 min readBarclays analyst Christopher Pasquale identifies Stryker (SYK) and Beta Bionics (BBNX) as attractive investment opportunities in the MedTech sector. SYK reported 2Q26 revenue of $6.6B, up 9.4% YoY, with an Overweight rating and $375 price target. BBNX reported 2Q26 revenue of $32M, up 38% YoY, with a positive outlook on market share growth.
3 min readBarclays initiated coverage of Beta Bionics with an Overweight rating and a $30 price target. The stock is currently trading at $18.63, down 4.02% year-to-date. Previously, Truist raised its price target to $28 with a Buy rating.
1 min readBeta Bionics (BBNX) faces a class action lawsuit after a 37% stock drop following disclosures of medical device safety issues. The lawsuit follows the sharp decline, with potential regulatory or financial impacts yet to be quantified.
1 min readBeta Bionics (BBNX) rose 6.8% to $25.53 after partnering with Senseonics to integrate its insulin delivery systems with Senseonics' Eversence 365 sensor. The first product is expected in Q4. CEO Sean Saint highlighted the expanded reach for diabetes management.
1 min readUltragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo
3 min readBeta Bionics completed a $172.5 million public offering. The company's stock has seen a 5-day change of 21.43 USD, a 1st Jan change of -3.38%, and a year-to-date change of +29.17%. BofA Securities recently adjusted its price target to $18 from $15.50.
1 min readHopman Mark (Chief Commercial Officer) sold 30,779 shares of Beta Bionics, Inc. (BBNX) at $20.13 ($0.62M total) on 2026-09-16 under a Rule 10b5-1 trading plan.
1 min read
